Repositioning Candidate Details

Candidate ID: R0108
Source ID: DB00301
Source Type: approved; investigational
Compound Type: small molecule
Compound Name: Flucloxacillin
Synonyms: (2S,5R,6R)-6-({[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 3-(2-Chloro-6-fluorophenyl)-5-methyl-4-isoxazolylpenicillin; Floxacillin; Flucloxacillin
Molecular Formula: C19H17ClFN3O5S
SMILES: [H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1F)C(O)=O
Structure:
DrugBank Description: Antibiotic analog of .
CAS Number: 5250-39-5
Molecular Weight: 453.872
DrugBank Indication: Used to treat bacterial infection by susceptible microorganisms.
DrugBank Pharmacology: Flucloxacillin is a penicillin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms. The name "penicillin" can either refer to several variants of penicillin available, or to the group of antibiotics derived from the penicillins. Flucloxacillin has <i>in vitro</i> activity against gram-positive and gram-negative aerobic and anaerobic bacteria. The bactericidal activity of Flucloxacillin results from the inhibition of cell wall synthesis and is mediated through flucloxacillin binding to penicillin binding proteins (PBPs). Flucloxacillin is stable against hydrolysis by a variety of beta-lactamases, including penicillinases, and cephalosporinases and extended spectrum beta-lactamases.
DrugBank MoA: By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, flucloxacillin inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that flucloxacillin interferes with an autolysin inhibitor.
Targets: Penicillin-binding protein 1A inhibitor
Inclusion Criteria: Indication associated